(Q34296526)

1 August 2017

title

Immunogenicity to biologics: mechanisms, prediction and reduction (English)

1 reference

1 August 2017

Jean Sathish

6

0 references

Munir Pirmohamed

object named as

Munir Pirmohamed

4

0 references

Swaminathan Sethu

1

object named as

Swaminathan Sethu

1 reference

1 August 2017

Karthik Govindappa

2

1 reference

1 August 2017

Mohammad Alhaidari

3

1 reference

1 August 2017

Kevin Park

5

1 reference

1 August 2017

publication date

29 August 2012

1 reference

Archivum Immunologiae et Therapiae Experimentalis

1 August 2017

published in

1 reference

1 August 2017

volume

60

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

331-344

1 reference

Antibodies against interferon-beta in multiple sclerosis

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Neutralizing antiviral B cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Expression and role of Fc- and complement-receptors on human dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The who, how and where of antigen presentation to B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The complement system in B cell regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Determinants of autoantibody induction by conjugated papillomavirus virus-like particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Mechanisms of adverse drug reactions to biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Regulated portals of entry into the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

From genome to vaccine—new immunoinformatics tools for vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Reducing risk, improving outcomes: bioengineering less immunogenic protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immunogenicity of protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Trends in risks associated with new drug development: success rates for investigational drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Recent advances in B-cell epitope prediction methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Predicting linear B-cell epitopes using string kernels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

HLA-DR-restricted T-cell responses to factor VIII epitopes in a mild haemophilia A family with missense substitution A2201P.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Role of repetitive antigen patterns for induction of antibodies against antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Anaphylaxis: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Mice Deficient in Complement Receptors 1 and 2 Lack a Tissue Injury-Inducing Subset of the Natural Antibody Repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immune complex-mediated enhancement of secondary antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Pathways for self-tolerance and the treatment of autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Intermolecular cooperativity: a clue to why mice have IgG3?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Strategies to improve the effect of vaccination in the elderly: the vaccine producer's perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Complement drives Th17 cell differentiation and triggers autoimmune arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Current and future approaches to inhibitor management and aversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Structure-immunogenicity relationships of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Thyrotropin receptor epitopes and their relation to histocompatibility leukocyte antigen-DR molecules in Graves' disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The Rebif new formulation story: it's not trials and error

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Antibody therapeutics: isotype and glycoform selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

PEGylation of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

T-cell regulation: with complements from innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

A systematic bioinformatics approach for selection of epitope-based vaccine targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Antibodies against erythropoietin and other protein-based therapeutics: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Lispro analog for treatment of generalized allergy to human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Coupling of aggregation and immunogenicity in biotherapeutics: T- and B-cell immune epitopes may contain aggregation-prone regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Prediction of MHC-peptide binding: a systematic and comprehensive overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Improved method for predicting linear B-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Protein therapeutics: a summary and pharmacological classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Thrombocytopenia caused by the development of antibodies to thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Marginal zone and B1 B cells unite in the early response against T-independent blood-borne particulate antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Decoding the patterns of self and nonself by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Effect of oromucosal administration of IFN-alpha on allergic sensitization and the hypersensitive inflammatory response in animals sensitized to ragweed pollen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

IgM Antibody Responses to Hepatitis B Surface Antigen in Recipients of Hepatitis B Virus Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Evaluation of the immuno-stimulatory potential of stopper extractables and leachables by using dendritic cells as readout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Regulatory T cells and mechanisms of immune system control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Histocompatibility antigens and alleles in Japanese haemophilia A patients with or without factor VIII antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Optimization of therapeutic proteins to delete T-cell epitopes while maintaining beneficial residue interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Impaired in vivo CD4+ T cell expansion and differentiation in aged mice is not solely due to T cell defects: decreased stimulation by aged dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Adverse side-effects to biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The association of anti-r-HuEpo-associated pure red cell aplasia with HLA-DRB1*09-DQB1*0309.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

(Re)defining biopharmaceutical

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immune dysfunction in the elderly and its reversal by antihistamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immunological aspects of inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Effects of protein aggregates: an immunologic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Bcipep: a database of B-cell epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Bioequivalence and the immunogenicity of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immunogenicity of therapeutic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

3D-Epitope-Explorer (3DEX): localization of conformational epitopes within three-dimensional structures of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Anaphylaxis after treatment with recombinant factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Aging and the dendritic cell system: implications for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Impact of product-related factors on immunogenicity of biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Analysis and prediction of protective continuous B-cell epitopes on pathogen proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope in human interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunog

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

How were new medicines discovered?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Rationally engineered therapeutic proteins with reduced immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

On the Role of Aggregates in the Immunogenicity of Recombinant Human Interferon Beta in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

The impact of glycosylation on HLA-DR1-restricted T cell recognition of type II collagen in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Protein aggregation and its inhibition in biopharmaceutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Determinants of antigenicity and specificity in immune response for protein sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Factor IX inhibitors and anaphylaxis in hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Adverse reactions to biological modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Human antibody-Fc receptor interactions illuminated by crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

Antibody-specified B-cell epitope prediction in line with the principle of context-awareness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0189-7

10.1007/S00005-012-0189-7

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1046284586

0 references

1 reference